# Cancer Survivors and Providers Differ on Cannabis Risk Awareness and Communication > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cancer-survivors-and-providers-differ-on-cannabis-risk-awareness-and-communication/ > **Published:** 2026-07-23T17:22:58-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:48:32-04:00 > **Clinical Summary:** Cancer survivors and providers differ on cannabis risk awareness. Learn key safety considerations and communication strategies for oncology practice. --- ✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. CancerResearchSafetyMental HealthPainAnxietyPolicy Why This Matters Clinicians treating cancer survivors need to understand that their patients may have significantly different perceptions of cannabis risks than medical evidence supports, which can lead to miscommunication about safety and efficacy. This gap in risk awareness between providers and patients highlights the need for standardized counseling approaches and updated clinical guidelines to ensure informed decision-making about cannabis use in the survivorship population. Improved provider-patient dialogue about cannabis is essential given the prevalence of use among cancer survivors and the limited evidence base for its therapeutic benefits in cancer care. Clinical Summary This study reveals a significant gap between cancer survivors’ and healthcare providers’ perceptions regarding [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/) and risk, with survivors and providers showing divergent levels of awareness about potential cannabis-related harms and benefits. The findings indicate that many cancer patients may be using cannabis without adequate counseling about risks, while providers may underestimate patient interest in or use of cannabis products for symptom management. This communication disconnect has important implications for oncology practice, as survivors increasingly turn to cannabis for pain, nausea, and [anxiety management](https://cedclinic.com/cannabis-and-ptsd-treatment-memory-loss-benefits/) without clear guidance from their care teams. The research underscores the need for standardized, evidence-based cannabis counseling protocols integrated into cancer care to ensure patients have accurate risk-benefit information when considering cannabis use. Clinicians managing cancer survivors should proactively initiate cannabis discussions, assess current or contemplated use, and provide evidence-based information about efficacy and safety in the oncology context rather than assuming patients will volunteer this information. Dr. Caplan’s Take “What this survey tells us is that we have a significant communication gap between what oncologists and cancer survivors understand about cannabis risks, and that’s worth taking seriously in clinical practice; we need better, evidence-based conversations with our patients rather than assuming either side has complete information.” Clinical Perspective 💊 Divergent risk perception between cancer survivors and their healthcare providers regarding cannabis presents a significant communication gap with potential clinical consequences. Survivors may underestimate cannabis-related harms or overestimate therapeutic benefits, particularly given limited high-quality evidence for cannabis in [cancer symptom management](https://cedclinic.com/cannabis-consumption-cancer-immunotherapy-outcomes/) and the lack of standardized dosing or quality control in most jurisdictions. Providers, conversely, may lack training in [cannabis pharmacology](https://cedclinic.com/cannabis-tolerance-behavioral-models/) and cannabinoid interactions with chemotherapy or supportive care medications, creating mutual uncertainty that inhibits productive dialogue. Rather than avoiding the discussion, clinicians caring for cancer patients should proactively assess cannabis use and intentions, acknowledge the evidence gaps honestly, and discuss documented risks including potential drug interactions, cognitive effects, and [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) in vulnerable populations. Establishing shared decision-making frameworks and staying informed about evolving clinical evidence will help providers guide survivors toward evidence-based symptom management while respecting their autonomy and maintaining trust. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cancer%20Survivors%20and%20Providers%20Differ%20on%20Cannabis%20Risk%20Awareness%20and%20Communication%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71269)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71269)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cancer%20Survivors%20and%20Providers%20Differ%20on%20Cannabis%20Risk%20Awareness%20and%20Communication%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D71269)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [The cannabis communication gap between cancer patients, providers: 5 notes](https://cedclinic.com/the-cannabis-communication-gap-between-cancer-patients-providers-5-notes/) - [Cancer survivors and providers differ in views on medical cannabis, study finds](https://cedclinic.com/cancer-survivors-and-providers-differ-in-views-on-medical-cannabis-study-finds/) - [Cancer survivors and providers differ in views on medical cannabis, study finds](https://cedclinic.com/cancer-survivors-and-providers-differ-in-views-on-medical-cannabis-study-finds/) 📰 Source: [https://ascopost.com/news/july-2026/cancer-survivors-and-providers-differ-on-cannabis-risk-awareness-and-communication/](https://ascopost.com/news/july-2026/cancer-survivors-and-providers-differ-on-cannabis-risk-awareness-and-communication/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).